James P. Crowley: A New Era in Cardiovascular Risk Prevention

James P. Crowley, Professor of Medicine Emeritus at Brown University, Captain at U.S. Navy Reserve, shared George Niles Mekeel‘s post on LinkedIn, adding:

“The recommendations incorporated an updated risk calculator released in 2023 and broadened eligibility by expanding the age range from 40-75 to 30— 79 and extending the risk horizon from 10 years to 30 years.

Age 30 is no longer considered too young to begin statins for high cholesterol levels!

‘The shift to a longer view of cardiovascular disease risk is a sea change for doctors in counseling patients,’ said Timothy S. Anderson, assistant professor of medicine, University of Pittsburgh; primary care physician, UPMC; and health quality researcher. ‘We wanted to better understand the potential population-health effect of this shift.’

Before the new guidelines, people who were flagged with high cholesterol in their 30s and 40s tended to be recommended to focus on diet and exercise and were not recommended medication-unless the patient already had heart disease or other factors that made them particularly high-risk, like diabetes.”

George Niles Mekeel, former Nurse Manager at the Madlyn Borelli Multiple Sclerosis Center, Montefiore Nyack Hospital, shared a post on LinkedIn:

“More than half of U.S. adults ages 30 to 79—about 87.5 million people—are now recommended for statins to prevent cardiovascular disease under newly updated clinical guidelines, according to a study by University of Pittsburgh School of Medicine researchers published July 20 in JAMA.

The new recommendations significantly change how doctors assess cardiovascular risk by looking beyond the next 10 years to a person’s risk over several decades.

Even though newer calculators often estimate lower short-term risk than older tools, the guidelines broaden statin eligibility. As a result, an additional 21.5 million Americans are now recommended for statins, bringing the total to 56.6% of adults ages 30 to 79.

In March 2026, the American Heart Association, the American College of Cardiology and others released updated guidelines for managing high cholesterol to help prevent cardiovascular events, including heart attacks and strokes.

The recommendations incorporated an updated risk calculator released in 2023 and broadened eligibility by expanding the age range from 40–75 to 30–79 and extending the risk horizon from 10 years to 30 years.

‘The shift to a longer view of cardiovascular disease risk is a sea change for doctors in counseling patients,’ said Timothy S. Anderson, assistant professor of medicine, University of Pittsburgh; primary care physician, UPMC; and health quality researcher. ‘We wanted to better understand the potential population-health effect of this shift.’

‘Before the new guidelines, people who were flagged with high cholesterol in their 30s and 40s tended to be recommended to focus on diet and exercise and were not recommended medication—unless the patient already had heart disease or other factors that made them particularly high-risk, like diabetes.’

The team analyzed data from 4,366 participants in the National Health and Nutrition Examination Survey, representing about 154.5 million U.S. adults who do not have existing cardiovascular disease, from 2017 to 2023.

The analysis focused specifically on primary prevention—reducing risk before a heart attack or stroke occurs—and did not include pregnant individuals in the study sample.

The results showed that age remains a strong predictor of risk. Relatively few—just 11.1%—of adults in their 30s are recommended statins. Eligibility increases steadily over time, with 85% of people in their 60s and most individuals in their 70s—93.5%—qualifying under the new guidelines.

The vast expansion of people recommended for treatment is heavily driven by patients who are generally considered to be at low risk in the shorter term, meaning they are under 3% risk of having a heart attack or stroke within 10 years, but modest risk—over 10%—within 30 years.”

Stay updated with Hemostasis Today.